Dublin, Aug. 05, 2024 (GLOBE NEWSWIRE) — The “Prostate Cancer Diagnostics Market Report by Type, Test Type, End User, Regions, and Company Analysis 2024-2032” report has been added to ResearchAndMarkets.com’s offering.
The global prostate cancer diagnostics market is experiencing a robust growth phase, with a projected compound annual growth rate (CAGR) of 12.35% from 2024 to 2032.
The market, which stood at US$ 4.17 billion in 2023, is anticipated to ascend to nearly US$ 11.89 billion by the end of the forecast period. This growth trajectory is attributed to the increasing prevalence of prostate cancer among aging populations and advancements in diagnostic technology.
Innovations in the field of medical diagnostics are expected to be a major driver for the market. The enhancements in imaging technologies such as MRI and PSMA-PET are aiding in the early detection and management of prostate cancer, which is critical for effective treatment. With a focus on personalized medicine, researchers are now able to tailor diagnostic and treatment regimens to the individual characteristics of patients, leading to more effective and targeted therapy options.
Asia-Pacific Market Accelerating
The Asia-Pacific region is witnessing a surge in the rate of prostate cancer incidence and awareness, thereby fueling the market growth. Notable investments in healthcare infrastructure, along with government-backed health initiatives, are contributing to the region’s readiness in managing this disease. Countries like Japan and India are taking proactive steps toward improving the diagnosis and treatment of prostate cancer, largely impacting the growth potential in these markets.
Leading Companies Spearheading Market Innovation
Key players within the global prostate cancer diagnostics market include F. Hoffman-La Roche AG, Bayer AG, Thermo Fisher Scientific Inc., and Abbott Laboratories Inc., each playing a pivotal role in the market’s development. These companies are consistently innovating and exploring new avenues in diagnostics, as evidenced by numerous collaborations and the integration of artificial intelligence in imaging data interpretation. These efforts are instrumental in enhancing the efficacy and accuracy of prostate cancer diagnostics.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 215 |
| Forecast Period | 2023 – 2032 |
| Estimated Market Value (USD) in 2023 | $4.17 Billion |
| Forecasted Market Value (USD) by 2032 | $11.89 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
Companies Featured
- F. Hoffman-La Roche AG
- Bayer AG
- Thermo Fisher Scientific Inc.
- Abbott Laboratories Inc.
- Siemens Healthineers AG
- Becton Dickinson and Company
- Agilent Technologies Inc.
- Hologic Inc
- Qiagen N.V.
- OPKO Health Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jxhcir
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Prostate Cancer Diagnostics Market
